EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Rational Design and Antimycobacterial Evaluation of Aryl Sulfonamide–Linked Isoniazid Hydrazones Against Mycobacterium Tuberculosis

Mukanda Gedeon Kadima, Sahil Mishra, Gobind Kumar, Pule Seboletswe, Afsana Kajee, Ankit, Françoise Roquet-Banères, Maëlle Foubert, Laurent Kremer, Rajshekhar Karpoormath iD, Parvesh Singh iD

ChemMedChem · 2025

DOI: 10.1002/cmdc.202500398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Mukanda Gedeon Kadima und 10 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Pharmaceutical Sciences, Westville Campus, University of KwaZulu-Natal, Durban, 4000, South Africa. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Antitubercular Agents, Isoniazid, Sulfonamides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation (SA), Vaincre la Mucoviscidose, Fondation pour la Recherche Médicale.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite significant advancements in antituberculosis (TB) drug discovery, considerable scope remains for novel therapeutic development. Molecular hybridization represents a promising strategy for generating new anti‐TB agents. In this study, in silico molecular docking is employed to design novel isoniazid–sulfonamide hybrids connected via a hydrazone bridge, designated as series 7j–r and 8a–i . Docking analysis reveals that these compounds interact significantly with the active site of InhA, particularly engaging the catalytic triad residues Y158, F149, and K165, as well as the cofactor NAD. Subsequently, both series are synthesized and evaluated against Mycobacterium tuberculosis . Generally, compounds from both series ( 7 and 8) exhibit enhanced activity compared to their precursors. Notably, compound 8a demonstrated approximately twofold greater potency ( minimum inhibitory concentration (MIC) = 0.156 µg mL −1 ) with respect to compound 7j (MIC = 0.313 µg mL −1 ). However, these compounds lose efficacy against INH‐resistant M. tuberculosis strains harboring katG mutations and remain ineffective against multidrug‐resistant and extensively drug‐resistant strains of M. tuberculosis . Encouragingly, the tested compounds exhibit little cytotoxicity against the THP‐1 human monocytic cell line at a concentration of 20 µg mL −1 . Additionally, the structural stability studies using 1 H NMR confirm the structural integrity of these compounds. Overall, these molecular hybrids are promising for further development as anti‐TB agents after relevant structural optimizations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisAntitubercular AgentsIsoniazidSulfonamidesHydrazonesDrug DesignMicrobial Sensitivity TestsHumansStructure-Activity RelationshipMolecular Docking SimulationMolecular StructureDose-Response Relationship, Drug

Stichwörter der Autor:innen

Mycobacterium tuberculosisflexibilityhydrazonesisoniazidmolecular dockingmolecular hybridsrigiditysulfonamides

Substanzen

Antitubercular AgentsIsoniazidSulfonamidesHydrazones

Autor:innen und Institutionen

  • Discipline of Pharmaceutical Sciences, Westville Campus, University of KwaZulu-Natal, Durban, 4000, South Africa.
  • School of Chemistry and Physics, University of KwaZulu-Natal, P/Bag X54001, Westville, Durban, 4000, South Africa.
  • Department of Microbiology, National Health Laboratory Services (NHLS), Inkosi Albert Luthuli Central Hospital, Durban, 4000, South Africa.
  • Centre National de la Recherche Scientifique UMR 9004, Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, 1919 route de Mende, 34293, Montpellier, France.
  • INSERM, IRIM, 34293, Montpellier, France.

ORCID-Profile: Rajshekhar Karpoormath, Parvesh Singh

Förderung

  • National Research Foundation (SA)
  • Vaincre la Mucoviscidose
  • Fondation pour la Recherche Médicale

Zitieren

APA

Kadima, M. G., Mishra, S., Kumar, G., Seboletswe, P., Kajee, A., Ankit, Roquet-Banères, F., Foubert, M., Kremer, L., Karpoormath, R., & Singh, P. (2025). Rational Design and Antimycobacterial Evaluation of Aryl Sulfonamide–Linked Isoniazid Hydrazones Against Mycobacterium Tuberculosis. ChemMedChem. https://doi.org/10.1002/cmdc.202500398

Vancouver

Kadima MG, Mishra S, Kumar G, Seboletswe P, Kajee A, Ankit, et al. Rational Design and Antimycobacterial Evaluation of Aryl Sulfonamide–Linked Isoniazid Hydrazones Against Mycobacterium Tuberculosis. ChemMedChem. 2025. doi:10.1002/cmdc.202500398

BibTeX
@article{Kadima2025,
  author = {Kadima, Mukanda Gedeon and Mishra, Sahil and Kumar, Gobind and Seboletswe, Pule and Kajee, Afsana and Ankit and Roquet-Banères, Françoise and Foubert, Maëlle and Kremer, Laurent and Karpoormath, Rajshekhar and Singh, Parvesh},
  title = {Rational Design and Antimycobacterial Evaluation of Aryl Sulfonamide–Linked Isoniazid Hydrazones Against Mycobacterium Tuberculosis},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202500398}
}
Kostenlos starten →